{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T15:53:26Z","timestamp":1791388406712,"version":"4.3.3"},"reference-count":28,"publisher":"BMJ","issue":"9","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["DTB"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:p>Polyendocrine metabolic ovarian syndrome (PMOS), previously named polycystic ovary syndrome, is a common endocrine disorder in women of reproductive age. It is associated with excessive levels of androgens and ovulatory dysfunction and has reproductive, metabolic and psychological impacts across the lifespan. Pharmacotherapy in PMOS should be directed at the concerns of the individual patient and may include the combined contraceptive pill, antiandrogen agents, metformin, antiobesity agents and ovulation induction agents. A narrative review of non-hormonal therapies was conducted. Metformin is associated with modest reductions in body weight and improves metabolic and anthropometric outcomes. Glucagon-like peptide-1 receptor agonists are an attractive option for weight loss although specific data in PMOS populations remain limited and there are safety considerations in the periconceptual setting. For ovulation induction, letrozole is the first-line agent of choice based on reassuring safety and efficacy data.<\/jats:p>","DOI":"10.1136\/dtb.2022.000065","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T17:20:41Z","timestamp":1782926441000},"page":"134-138","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacological treatment of polyendocrine metabolic ovarian syndrome in adults"],"prefix":"10.1136","volume":"64","author":[{"given":"Lucy","family":"Prentice","sequence":"first","affiliation":[{"name":"Obstetrics, Gynaecology and Reproductive Sciences, The University of Auckland \u2013 Grafton Campus, Auckland, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Rassie","sequence":"additional","affiliation":[{"name":"Monash Centre for Health Research and Implementation, Clayton, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"2026100708151174000_64.9.134.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2023.07.025"},{"key":"2026100708151174000_64.9.134.2","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1016\/S0140-6736(26)00717-8","article-title":"Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process","volume":"407","author":"Teede","year":"2026","journal-title":"Lancet"},{"key":"2026100708151174000_64.9.134.3","doi-asserted-by":"crossref","unstructured":"Legro RS , Kovacs GT , Fauser B . Polycystic ovary syndrome: from phenotype to genotype. Cambridge University Press, 2022:8\u201320.","DOI":"10.1017\/9781108989831.002"},{"key":"2026100708151174000_64.9.134.4","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/S2213-8587(22)00163-2","article-title":"Polycystic ovary syndrome","volume":"10","author":"Joham","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026100708151174000_64.9.134.5","doi-asserted-by":"crossref","DOI":"10.1136\/bmjmed-2023-000548","article-title":"Polycystic ovary syndrome: pathophysiology and therapeutic opportunities","volume":"2","author":"Dong","year":"2023","journal-title":"BMJ Med"},{"key":"2026100708151174000_64.9.134.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2003.10.004"},{"key":"2026100708151174000_64.9.134.7","article-title":"Lifestyle changes in women with polycystic ovary syndrome","volume":"3","author":"Lim","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"2026100708151174000_64.9.134.8","first-page":"187","article-title":"Metformin-clinical pharmacology in PCOs","volume":"8","author":"Dumitrescu","year":"2015","journal-title":"J Med Life"},{"key":"2026100708151174000_64.9.134.9","doi-asserted-by":"crossref","first-page":"109","DOI":"10.18773\/austprescr.2024.030","article-title":"Pharmacological management of polycystic ovary syndrome","volume":"47","author":"Ee","year":"2024","journal-title":"Aust Prescr"},{"key":"2026100708151174000_64.9.134.10","doi-asserted-by":"publisher","DOI":"10.1093\/ejendo\/lvad098"},{"key":"2026100708151174000_64.9.134.11","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/des463"},{"key":"2026100708151174000_64.9.134.12","doi-asserted-by":"crossref","DOI":"10.1530\/EC-24-0529","article-title":"Endocrine and metabolic effects of GLP-1 receptor agonists on women with PCOS, a narrative review","volume":"14","author":"Monney","year":"2025","journal-title":"Endocr Connect"},{"key":"2026100708151174000_64.9.134.13","doi-asserted-by":"publisher","DOI":"10.1210\/en.2014-1978"},{"key":"2026100708151174000_64.9.134.14","doi-asserted-by":"crossref","DOI":"10.1111\/obr.13704","article-title":"Anti-obesity pharmacological agents for polycystic ovary syndrome: A systematic review and meta-analysis to inform the 2023 international evidence-based guideline","volume":"25","author":"Goldberg","year":"2024","journal-title":"Obes Rev"},{"key":"2026100708151174000_64.9.134.15","article-title":"Semaglutide Versus Other Glucagon-Like Peptide-1 Agonists for Weight Loss in Type 2 Diabetes Patients: A Systematic Review and Meta-Analysis","volume":"16","author":"Wen","year":"2024","journal-title":"Cureus"},{"key":"2026100708151174000_64.9.134.16","doi-asserted-by":"crossref","first-page":"800","DOI":"10.5935\/1518-0557.20250162","article-title":"Incretins (GLP-1 Receptor Agonists) and Polycystic Ovaries","volume":"29","author":"Piazza","year":"2025","journal-title":"JBRA Assist Reprod"},{"key":"2026100708151174000_64.9.134.17","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.r1606","article-title":"Side effects of GLP-1 receptor agonists","volume":"390","author":"Manne-Goehler","year":"2025","journal-title":"BMJ"},{"key":"2026100708151174000_64.9.134.18","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2023-083550","article-title":"Use of GLP1 receptor agonists in early pregnancy and reproductive safety: a multicentre, observational, prospective cohort study based on the databases of six Teratology Information Services","volume":"14","author":"Dao","year":"2024","journal-title":"BMJ Open"},{"key":"2026100708151174000_64.9.134.19","unstructured":"Healthcare, F.o.S.a.R . FSRH statement: glucagon-like peptide-1 (GLP-1) agonists and oral contraception. London, UK: Faculty of Sexual and Reproductive Healthcare, 2025."},{"key":"2026100708151174000_64.9.134.20","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-025-04200-0","article-title":"Trajectory of the body weight after drug discontinuation in the treatment of anti-obesity medications","volume":"23","author":"Wu","year":"2025","journal-title":"BMC Med"},{"key":"2026100708151174000_64.9.134.21","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1001\/jama.2025.20951","article-title":"Gestational Weight Gain and Pregnancy Outcomes After GLP-1 Receptor Agonist Discontinuation","volume":"334","author":"Maya","year":"2025","journal-title":"JAMA"},{"key":"2026100708151174000_64.9.134.22","article-title":"Aromatase inhibitors (letrozole) for ovulation induction in infertile women with polycystic ovary syndrome","volume":"9","author":"Franik","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"2026100708151174000_64.9.134.23","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/humupd\/dmaa055","article-title":"Risk of foetal harm with letrozole use in fertility treatment: a systematic review and meta-analysis","volume":"27","author":"Pundir","year":"2021","journal-title":"Hum Reprod Update"},{"key":"2026100708151174000_64.9.134.24","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/GCO.0b013e32833beebf","article-title":"Letrozole for ovulation induction and controlled ovarian hyperstimulation","volume":"22","author":"Pritts","year":"2010","journal-title":"Curr Opin Obstet Gynecol"},{"key":"2026100708151174000_64.9.134.25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1313517"},{"key":"2026100708151174000_64.9.134.26","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1080\/09513590.2017.1332174","article-title":"Comparison of clomiphene citrate and letrozole for ovulation induction in women with polycystic ovary syndrome: a prospective randomized trial","volume":"33","author":"Liu","year":"2017","journal-title":"Gynecol Endocrinol"},{"key":"2026100708151174000_64.9.134.27","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1007\/s00404-019-05064-5","article-title":"The effectiveness of inositol and metformin on infertile polycystic ovary syndrome women with resistant to letrozole","volume":"299","author":"Pourghasem","year":"2019","journal-title":"Arch Gynecol Obstet"},{"key":"2026100708151174000_64.9.134.28","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.fertnstert.2017.06.026","article-title":"Role of metformin for ovulation induction in infertile patients with polycystic ovary syndrome (PCOS): a guideline","volume":"108","author":"Penzias","year":"2017","journal-title":"Fertil Steril"}],"container-title":["Drug and Therapeutics Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/dtb.2022.000065","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T15:15:23Z","timestamp":1791386123000},"score":1,"resource":{"primary":{"URL":"https:\/\/dtb.bmj.com\/lookup\/doi\/10.1136\/dtb.2022.000065"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":28,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9,3]]},"published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1136\/dtb.2022.000065"],"URL":"https:\/\/doi.org\/10.1136\/dtb.2022.000065","relation":{},"ISSN":["0012-6543","1755-5248"],"issn-type":[{"value":"0012-6543","type":"print"},{"value":"1755-5248","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]}}}